BioFactura

BioFactura develops and manufactures high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals), biodefense medical countermeasures, and client-selected novel drugs using its patented StableFastTM Biomanufacturing Platform, the optimal choice for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 15 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug and vaccine development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.